Kornimate/medical-research-clean huggingface dataset:
individualized automatic coaching message for glycemic management and depressive symptom

Conditions: Diabetes Mellitus, Type 1; Continuous Glucose Measurement

Summary: this is a single-center, randomized, prospective, confirmatory study of efficacy of individualized automatic coaching message for glycemic management and depressive symptom in patients with type 1 diabetes. the study will enroll patients with type 1 diabetes who are applying continuous glucose monitoring (cgm) and receiving twice-monthly non-face-to-face management by a dedicated education nurse through the type 1 diabetes home care project and educational consultation program. for 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management. the control group will continue their current treatment and non-face-to-face diabetes management. the aim of this study is to evaluate whether the efficacy of automated, personalized coaching messages for glycemic management and depressive symptoms is non-inferior to the current non-face-to-face management approach in people with type 1 diabetes.


Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes, age 18-75 years old * patients who have used continuous glucose monitoring at least three months and have enrolled in type 1 diabetes home care project and educational consultation program. * patients with at least 70% of 14 days of continuous glucose monitor data within the past month * glycated hemoglobin 7% or higher, or glycated hemoglobin 6% or higher but less than 7% and failing to meet 1 of the continuous glucose monitor blood glucose target values: time in range (70-180 mg/l) 70% or less, or time below range (\ 180 mg/l) 25% or more, or glucose management indicator (gmi) 7% or more, or coefficient of variation (cv%) 36% or more. * currently receiving treatment with multiple insulin injection therapy * patients who have access to kakaotalk via smartphone and are able to communicate with it * voluntarily agreed to participate in this clinical study. exclusion criteria: * steroid and immunosuppressant users. but it can be included if patients continuously maintain same drug dose at least three months. * breastfeeding or pregnant patients * patients who do not voluntarily consent to the study * anyone deemed unsuitable by the investigator to participate in the study

Keywords: type 1 diabetes continuous glucose monitoring depressive symptom
ivabradine to improve endothelial function in patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: this study evaluates the effect of ivabradine on endothelial function in patients with coronary artery disease (cad) after complete revascularization with percutaneous coronary angioplasty (pci). at least 30 days after pci, patients will be randomized to receive ivabradine 5 mg twice daily or to continue with standard medical therapy.


Eligibility criteria:
inclusion criteria: * history of stable coronary disease * complete coronary revascularization with pci at least 1 month prior to recruitment * sinus rhythm * absence of anginal symptoms exclusion criteria: * resting heart rate \<60 beats per minute * severe reduction of left ventricle ejection fraction (\<40%) * coronary artery by-pass surgery * myocardial infarction, stroke or cerebral transient ischemic attack within the previous 6 months * implanted pacemaker, cardioverter, or defibrillator * sick sinus syndrome * sinoatrial block * congenital long qt * complete atrioventricular block
analysis of vital signs in patients with covid-19

Conditions: Respiratory Disease

Summary: this project will use data obtained from a proprietary vision-based patient monitoring and management system (oxevision) for measuring heart rate and respiratory rate which is in clinical use at the coventry and warwickshire partnership nhs trust.

the investigators will analyse data from patients with known covid 19 infection both during, and where possible before clinical covid 19 infection and controls to determine whether changes can be detected in these parameters that precede overt clinical deterioration. the role of remote vision-based patient monitoring and management in supporting the care of patients with covid-19 will be assessed through staff interviews.

Eligibility criteria:
inclusion criteria: * patients age 18 and above. patients on wards with a medical diagnosis of covid 19 who are in rooms with the vision based patient monitoring and management system. exclusion criteria: children will be excluded. no data will be excluded unless specifically requested by the treating clinician.

Keywords: breathing rate pulse rate covid 19 patient monitoring
novel equations for estimating lean body mass in patients with chronic kidney disease

Conditions: Lean Body Mass; Chronic Kidney Diseases

Summary: simplified methods to estimate lean body mass (lbm), an important nutritional measure representing muscle mass and somatic protein, are lacking in non-dialyzed patients with chronic kidney disease (ckd). objective: we developed and tested a reliable equations for estimation of lbm in daily clinical practice.

two cross-sectional data sets were derived from outpatients with ckd stage 3-5 in peking university first hospital.two equations for estimating lbm based on midarm muscle circumference (mamc) or hand grip strength (hgs)were developed and validated in ckd patients with dual-energy x-ray absorptiometry (dexa) as referenced gold method. demographic data, comorbidity, and other clinical variables were also recorded.

Eligibility criteria:
inclusion criteria: * non-dialyzed patients with ckd stage 3-5 * clinical stable * a willingness to be examined with all measurements being taken simultaneously. exclusion criteria: * systemic infections, acute cardiovascular events, operations, trauma, active hepatitis or tumor * severe edema within one month prior to the study * chronic infections, connective tissue disease, hyper- or hypothyroidism, amputations or pregnancy, * taking immunosuppressive agents and anti-inflammatory medication chronically

Keywords: mid-arm muscle circumference handgrip strength dual-energy x-ray absorptiometry
characterization of adult subjects for asthmatic research studies

Conditions: Asthma

Summary: this study is designed to characterize subjects in terms of the nature and severity of their asthma and in terms of conditions that may alter the clinical expression of asthma. some features will be obtained in all subjects. these include a medical history and baseline lung function tests. this characterization forms the basis for our database that facilitates research protocols.

the purpose of this study is to generate a cohort of well-characterized asthmatic subjects as a resource for recruitment of asthmatic subjects and healthy controls in clinical studies and clinical trials in the ucsf airway clinical research center. the ucsf airway clinical research center (acrc) conducts multiple clinical research studies in asthma funded by the nih, foundations, and industry. we have a broad range of research interests, but we have specific interests in mechanism-oriented clinical studies and specific expertise in biospecimen collection, biobanking, and biospecimen analysis. our model is to have multiple studies recruiting simultaneously, and this means that we need well-organized recruitment and database systems. additionally, we aim to characterize asthmatic subjects in multiple domains, including disease severity, airway inflammation subtypes, and mucus subtypes. asthma is a heterogeneous disease in its clinical presentation and in its underlying cellular and molecular phenotypes. to explore cellular and molecular phenotypes of asthma, we will analyze induced sputum for cell types and gene expression, with a focus on th2 inflammation pathways and innate and adaptive immune cells that drive th2 inflammation. detailed cellular analysis of sputum is possible but requires that multiple sputum samples be collected for processing in multiple different ways, including by cytocentrifugation, facs analysis, and by formalin fixation and paraffin embedding of sputum cell pellets. we are also studying mucus phenotypes of asthma using methods of rheology, which needs to be done on fresh sputum.

Eligibility criteria:
inclusion criteria: * age 18 years and older exclusion criteria: * history of lung disease other than asthma * an upper respiratory tract infection or an exacerbation of their asthma within the preceding 4-6 weeks. * persons who have smoked \> 5 cigarettes per month and have a total pack-year smoking history \> 10 packs.
rare, but not alone: a large italian network to empower the impervious diagnostic pathway of rare cerebrovascular diseases (aligned)

Conditions: CADASIL; CADASIL (Diagnosis); Moya Moya Disease; Moyamoya; Moyamoya Syndrome; Sneddon Syndrome; Fabry Disease; COL4A1\2

Summary: cerebrovascular diseases (cvds) are one leading cause of morbidity and mortality worldwide. despite intensive investigations, more than 30% of strokes remain of undetermined origin. rare cerebrovascular diseases (rcvds), including heritable (i.e., cadasil, col4a1 syndrome, fabry disease) and acquired conditions (i.e., sneddon syndrome, moyamoya arteriopathy) account for a proportion of these strokes. however, rcvds are often misdiagnosed since clinicians are not able to recognize them. although rare, the identification of these stroke causes is important to establish appropriate management measures, including genetic counselling, and, if available, therapy. the lack of data on phenotype and clinical course of rcvds, given the paucity of published series, makes the diagnosis and the development of therapies challenging. furthermore, the molecular characterization of rcvds is still lacking, despite progresses achieved in common stroke by applying high throughput approaches as multi-omics. since the diagnosis and care of rcvds require adequate expertise and instrumental tools, clinical and research activities are usually reserved to few specialized centers, mostly located in the north of italy, leading patients to expensive trips for consultations. therefore, the creation of a clinical and research network aimed at improving the diagnostic pathways of rcvds is highly needed to improve the number of patients with rcvds to better define the clinical phenotype and to transfer the knowledge on rcvds in other centers overall italy filling the geographical gap affecting southern italy.


Eligibility criteria:
inclusion criteria: * patients with a clinical, genetic and/or neuroradiological diagnosis of rcvd (cadasil, fabry's disease, col4a1, sneddon's syndrome or moyamoya arteriopathy), who have had at least one brain mri study; exclusion criteria: * na

Keywords: rare cerebrovascular diseases italian network cadasil col4a1 syndrome fabry disease sneddon syndrome moyamoya arteriopathy col4a1/2
effect of kinesio taping and laser therapy in patient with lymphedema on girth measurement

Conditions: Lymphedema; Breast Cancer Stage II

Summary: find out the difference in the effect of kinesio taping and low level laser therapy on 66 patients with post mastectomy lymphedema as regards the following outcomes: 1.girth measurement between the upper limbs 2.) spadi 3) hand grip strength 4)the quality of life by cancer specific questionnaire.

60 females with bcrl will be recruited in this study for 4 weeks , their age ranged from 400 to 55 years old with stege 1,2 lymphedema and randomly divided into 3 equal groups: 2) study group (a) include 20 females with unilateral bcrl will receive kinesio taping plus manual lymphatic drainage , exercise and advices 3) study group (b) include 20 females with unilateral bcrl will receive low level laser therapy plus manual lymphatic drainage , exercise and advices 4) study group (c) include 20 females with unilateral bcrl will receive kinesio taping plus low level laser therapy and manual lymphatic drainage , exercise and advices regards the following outcomes: 1.girth measurement between the upper limbs 2.) spadi 3) hand grip strength 4)the quality of life by cancer specific questionnaire.

Eligibility criteria:
inclusion criteria: * persistence of lymphedema following mastectomy or breast conservative surgery for at least 3 months * minimum volume difference of 200 ml or an average difference in arm circumference of 2 cm or 10% between healthy and affected limbs. * femal with unilateral lymphedema from 40 to 55 years old exclusion criteria: * • any disease lead to swelling * medication especially diuretics * allergy * infection * pregnancy * heart band kidney disease * bilateral lymphedema * skin disease * chronic inflammatory disease

Keywords: laser taping
an extended access program (eap) for perampanel

Conditions: Primary Generalized Tonic-Clonic or Partial Onset Seizures; Lennox Gastaut Syndrome

Summary: the main objective of this eap is to ensure that participants participating in study e2007-g000-332, study e2007-g000-311, e2007-g000-238, e2007-g000-338 or eap e2007-g000-401 continue to have access to perampanel until such time that the appropriate formulation of perampanel becomes commercially available in the country in which they reside or until no participants remain in the eap.


Eligibility criteria:
inclusion criteria: 1. participants who have completed their participation in study e2007-g000-332, study e2007-g000-311, e2007-g000-238, e2007-g000-338, or who are being rolled over from eap e2007-g000-401 and, who in the opinion of the treating physician, continue to demonstrate a positive benefit-to-risk ratio from treatment with perampanel. 2. participants who provide informed consent where applicable per local requirements. 3. female participants of childbearing potential must agree for the duration of the program and for a period of at least 1 month following last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (example, a double-barrier method \[condom plus spermicide, condom plus diaphragm with spermicide\]). exclusion criteria: 1. participants who reside in countries where the appropriate formulation of perampanel is commercially available. 2. female participants who are nursing, pregnant, or planning to become pregnant.

Keywords: perampanel fycompa primary generalized tonic-clonic seizures e2007-g000-332 e2007
asia coma electrical stimulation (the aces trial)

Conditions: TBI (Traumatic Brain Injury)

Summary: this study is a prospective multicenter randomized controlled trial from asian countries to compare the effect and safety of right median nerve stimulation versus traditional treatment for comatose patients at the early stage following traumatic brain injury.

traumatic brain injury (tbi) is a leading cause of mortality and morbidity and one of the greatest unmet needs in public health. the most severe injury can lead to a poor outcome and prolonged coma of the victims. it is estimated that ten to fifteen percent of the severe tbi patients are discharged in a prolonged coma or a vegetative state. however, no treatment measure to data has been proven robustly to alter the pace of recovery or improve neurological outcome of the comatose patients following tbi. although right median nerve electrical stimulation (rmns) has been used clinically for more than two decades, no strong evidence of efficacy was generated because of the limitations in the past trials including a small sample size or the inappropriate study design. in the present study, a multicenter research network with inclusion of neurotrauma centers from china, india, nepal and kazakhstan was established with the aim to validate the efficacy and safety of a promising intervention strategy for traumatic coma at early stage. since rmns is a simple, inexpensive, noninvasive technique with a good safety profile, our study will probably add more evidence to the treatment of traumatic coma in asian countries.

Eligibility criteria:
inclusion criteria: * a confirmed history of closed traumatic brain injury 10 days before enrollment * a glasgow coma scale (gcs) score of 4-8 or the motor part less than 5 if the patient received tracheotomy. * 18-65 years of age exclusion criteria: * unstable vital signs * have a history of severe cardiac arrhythmias, implanted pacemaker, as well as seizures * pregnancy * no informed consent

Keywords: coma traumatic brain injury median nerve stimulation
role of triggering receptor expressed on myeloid cells (trem-1) as a novel biomarker in human epidermal growth factor receptor -2 (her-2) negative breast cancer: a molecular and clinical study

Conditions: Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Invasive

Summary: global cancer statistics by world region for the year 2022 estimated breast cancer the 2nd cause of new cancer cases (11.6%). (1) approximately 80% of all breast cancers (bcs) are currently categorized as human epidermal growth factor receptor 2 (her2)-negative. (2) most breast cancer cases can be cured by multimodality treatment, although cure rates vary by clinical stage, subtype and the clinical behavior of cancer which affected by the composition of pro- and anti-tumor immune mediators within the tumor microenvironment. (3, 4) immune gene signatures in breast tumors -that comprise genes with specialized roles in immune biology- significantly, have been shown to correlate with patient survival outcomes. (5-8)chemotherapy responsiveness. (7, 9), and more recently, response to immunotherapies.(10-12)one such candidate, the gene encoding triggering receptor expressed on myeloid cells (trem)-1, which emerged as a robust therapy predictive and prognostic marker. trem1 encodes a type i trans-membrane receptor of the ig superfamily expressed by effectors of innate immunity including neutrophils, monocytes and macrophages. the trem-1 receptor is known to augment inflammatory signaling in response to infectious pathogens by promoting release of cytokines that modulate the activation, recruitment and survival of myeloid and lymphoid cells. (13) in this study we hope to gain a better understanding of trem-1 clinical and molecular relevance in her2 negative bc either triple negative or hormonal positive which represent significant subset that lack target therapeutic options, evaluating its effect as predictive and prognostic marker and so the potential implications for patient management.

a prospective observational cohort study on the role of trem-1 as a novel immune biomarker in her-2 breast cancer it's a molecular and clinical study. our aim is to assess prognostic significance of trem-1 expression at baseline and post neo-adjuvant treatment regards dfs \& os and to quantify trem-1 expression and correlate its level with clinical and pathological response to neo-adjuvant treatment. and evaluate its association with immune cells (eg. monocytes and neutrophils)

Eligibility criteria:
inclusion criteria: * female patient aged \< 18 yrs. old * histological proven breast cancer * her-2 negative (hormonal positive or triple negative) * planned to receive neo-adjuvant therapy * complete clinical, radiological and therapeutic data exclusion criteria: * metastatic breast cancer * her-2 positive * incomplete clinical, radiological or therapeutic data

Keywords: trem-1 in non metastatic her-2 negative breast cancer
comparison of biolimus-eluting biodegradable polymer, everolimus-eluting and sirolimus-eluting coronary stents

Conditions: Coronary Artery Disease

Summary: to compare the safety and efficacy of coronary stenting with everolimus-eluting stent (promus element®) and biolimus-eluting stent with biodegradable polymer (nobori®)


Eligibility criteria:
inclusion criteria: * significant coronary artery stenosis (\> 50% by visual estimate) * stable angina, unstable angina, non-st elevation myocardial infarction (nstemi) and documented silent ischemia * patients eligible for intracoronary stenting * age ≥ 20 years old exclusion criteria: * st segment elevation myocardial infarction (within 24 hours) * low ejection fraction (\< 25%) * cardiogenic shock * history of bleeding diathesis or known coagulopathy * limited life-expectancy (less than 1 year) due to combined serious disease * contraindication to heparin, sirolimus, everolimus and biolimus * contraindication to aspirin and clopidogrel * pregnancy

Keywords: coronary artery disease stent
a clinical trial to evaluate the effect of concentrace trace mineral drops on gut health

Conditions: Gut Health; Bowel Movements; Constipation; Bloating

Summary: this is a virtual single-arm trial that will last 12 weeks. participants will take the drops daily and complete questionnaires at baseline, week 4, week 8, and week 12. gut health, bowel movements, stool looseness, constipation, bloating, and regularity will be evaluated at the baseline and at each check-in. likert scale responses will be statistically compared from baseline to each check-in. participant responses and product feedback will be presented as percentage scores.


Eligibility criteria:
inclusion criteria: * be male or female. be aged over 18. have a bmi less than 35. have issues with digestion, heartburn, indigestion, gas, or constipation. be willing to maintain their standard dietary pattern, activity level, and body weight for the duration of the study. be generally healthy - must not live with any uncontrolled disease. exclusion criteria: * any person with a pre-existing chronic condition that might prevent the participant from adhering to the protocol, including any oncological and psychiatric disorders. anyone taking any prescribed medication targeting the gut. anyone taking any supplements targeting the gut within the past month. anyone with any known severe allergic reactions. women who are pregnant, breastfeeding, or attempting to become pregnant. anyone unwilling to follow the study protocol.